We are live on ! Find out more
Calamos Advisors

Calamos Advisors Portfolio holdings

AUM $28.2B
1-Year Est. Return 21.78%
This Fund
S&P 500
This Quarter Est. Return
+0.71%
1 Year Est. Return
+21.78%
3 Year Est. Return
+69.57%
5 Year Est. Return
+92%
10 Year Est. Return
+282.63%
AUM
$22.9B
AUM Growth
+$1.01B
Cap. Flow
-$5.41B
Cap. Flow %
-23.63%
Top 10 Hldgs %
20.65%
Holding
1,090
New
128
Increased
343
Reduced
93
Closed
104

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$41.8M
2
AAPL icon
Apple
AAPL
+$35.4M
3
AMZN icon
Amazon
AMZN
+$34.6M
4
AESC
The AES Corporation
AESC
+$30.3M
5
ADBE icon
Adobe
ADBE
+$25.6M

Sector Composition

Rank Sector Weight
1 Technology 15.1%
2 Financials 8.11%
3 Healthcare 7.32%
4 Consumer Discretionary 6.91%
5 Communication Services 6.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLDR
526
DELISTED
Cloudera, Inc.
CLDR
$3.19M 0.01%
+200,000
New +$3.17M
SRE icon
527
Sempra
SRE
$59.2B
$3.17M 0.01%
+50,120
New +$3.31M
ORGO icon
528
Organogenesis Holdings
ORGO
$326M
$3.12M 0.01%
218,895
+32,508
+17% +$505K
RBC icon
529
RBC Bearings
RBC
$18.2B
$3.07M 0.01%
+14,475
New +$3.14M
VRAY
530
DELISTED
ViewRay, Inc.
VRAY
$3.06M 0.01%
424,285
-23,117
-5% -$146K
DTRTU
531
DELISTED
DTRT Health Acquisition Corp. Unit
DTRTU
$3.03M 0.01%
+300,000
New +$3.02M
OSTRU
532
DELISTED
Oyster Enterprises Acquisition Corp. Unit
OSTRU
$3.02M 0.01%
302,300
EQHA.U
533
DELISTED
EQ Health Acquisition Corp. Units, each consisting of one share of Class A common stock and one-half of one redeemable warrant
EQHA.U
$3.01M 0.01%
300,700
AKLI
534
DELISTED
Akili Inc
AKLI
$2.98M 0.01%
300,000
+100,000
+50% +$987K
SBEAU
535
DELISTED
SilverBox Engaged Merger Corp I Units
SBEAU
$2.98M 0.01%
300,000
ANZUU
536
DELISTED
Anzu Special Acquisition Corp I Units
ANZUU
$2.97M 0.01%
300,000
CCAIU
537
DELISTED
Cascadia Acquisition Corp. Unit
CCAIU
$2.97M 0.01%
+300,000
New +$2.96M
DNAB
538
DELISTED
Social Capital Suvretta Holdings Corp. II Class A Ordinary Shares
DNAB
$2.96M 0.01%
300,000
+100,000
+50% +$985K
OHPAU
539
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$2.96M 0.01%
300,000
CPARU
540
DELISTED
Catalyst Partners Acquisition Corp. Unit
CPARU
$2.96M 0.01%
300,000
ASZ.U
541
DELISTED
Austerlitz Acquisition Corporation II Units, each consisting of one Class A ordinary share and one-fourth of one redeemable warrant
ASZ.U
$2.96M 0.01%
300,000
DNAD
542
DELISTED
Social Capital Suvretta Holdings Corp. IV Class A Ordinary Shares
DNAD
$2.94M 0.01%
300,000
+100,000
+50% +$984K
PROK icon
543
ProKidney
PROK
$316M
$2.94M 0.01%
300,000
+100,000
+50% +$985K
SMIHU
544
DELISTED
Summit Healthcare Acquisition Corp. Units
SMIHU
$2.94M 0.01%
292,080
-7,920
-3% -$79.4K
ORMP icon
545
Oramed Pharmaceuticals
ORMP
$171M
$2.91M 0.01%
+132,145
New +$2.25M
LSCC icon
546
Lattice Semiconductor
LSCC
$16.4B
$2.9M 0.01%
44,878
-25,505
-36% -$1.51M
TEAM icon
547
Atlassian
TEAM
$25.4B
$2.86M 0.01%
7,300
+1,900
+35% +$635K
VICI icon
548
VICI Properties
VICI
$29.8B
$2.84M 0.01%
+100,000
New +$3.05M
CNDA.U
549
DELISTED
Concord Acquisition Corp II Units, each consisting of one share of Class A Common Stock and one-third of one Warrant
CNDA.U
$2.76M 0.01%
+276,950
New +$2.74M
DHBCU
550
DELISTED
DHB Capital Corp. Unit
DHBCU
$2.72M 0.01%
275,000
+100,000
+57% +$992K

Similar funds

Calamos Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Calamos Advisors held 1,090 positions worth $22.9B, up 4.6% from $21.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Calamos Advisors withdrew a net $5.41B in Q3 2021, closing 104 positions and reducing 93 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $31.2M position sold in full.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Calamos Advisors opened a new position in AstraZeneca worth $17.8M.

  • Calamos Advisors's largest Q3 2021 buy was AstraZeneca: 148,454 shares worth $17.8M.
  • Calamos Advisors added most to Microsoft in Q3 2021, an estimated $41.8M increase.
  • Calamos Advisors's biggest Q3 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $236M.
  • Calamos Advisors fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $31.2M.
  • Calamos Advisors's ten largest holdings make up 21% of its $22.9B portfolio in Q3 2021.
  • Calamos Advisors opened 128 new positions and closed 104 in Q3 2021.
  • Calamos Advisors's portfolio value rose 4.6% quarter-over-quarter to $22.9B.

Based on Calamos Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.